# Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer

> **NCT00198237** · PHASE2 · COMPLETED · sponsor: **Indiana University** · enrollment: 40 (—)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** docetaxel & capecitabine

## Key facts

- **NCT ID:** NCT00198237
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 40 (—)
- **Last updated:** 2014-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00198237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00198237, "Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00198237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*